Amresh Raina, MD
Advanced Heart Failure and Transplant Cardiology · Pittsburgh, PANPI 1447450705
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,050 of the $4,440 with a category attached, or 68.7%. Merck accounts for 70.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $3,192 and has fallen 90.9% since, to $289 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in PA, where the typical reported total is $4,440.
Across 41 payments — averaging $108.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3K
- Abbott$325
- Actelion Pharmaceuticals US, Inc.$318
- Bayer$224
- United Therapeutics Corporation$81
- E.r. Squibb & Sons, L.L.C.$67
- plus $297 from 8 others
Across 209 payments — averaging $3649.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$417K
- United Therapeutics Corporation$182K
- Janssen Research & Development, LLC$144K
- Bayer$19K
- Novartis$140
What the payments were for
- Consulting fees$3,05069%
- Food & beverage$1,28029%
- Education$1102%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 4 | $3,127 |
| Abbott | 7 | $325 |
| Actelion Pharmaceuticals US, Inc. | 6 | $318 |
| Bayer | 2 | $224 |
| United Therapeutics Corporation | 3 | $81 |
| E.r. Squibb & Sons, L.L.C. | 5 | $67 |
| Johnson & Johnson | 2 | $64 |
| Pfizer | 4 | $61 |
| Vifor Pharma, Inc. | 3 | $57 |
| Sandoz | 1 | $30 |
| Medtronic | 1 | $28 |
| Amgen | 1 | $25 |
| Novartis | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$224
- CARDIOMEMS$141
- All-In-One$106
How this compares
$4,440 in reported general payments places this provider in the 50th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
See all advanced heart failure and transplant cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 38 | $1,040,358 |
| UptraviSelexipag | 40 | $907,549 |
| Tyvaso DpiTreprostinil | 32 | $832,046 |
| AdempasRiociguat | 54 | $716,743 |
| WinrevairSotatercept-Csrk | 28 | $398,430 |
| OpsumitMacitentan | 28 | $340,714 |
| VyndaqelTafamidis Meglumine | 11 | $245,655 |
| EntrestoSacubitril/Valsartan | 154 | $172,265 |
| LetairisAmbrisentan | 13 | $159,261 |
| EliquisApixaban | 110 | $123,972 |
| Ambrisentan | 31 | $78,278 |
| JardianceEmpagliflozin | 52 | $46,901 |
| AdcircaTadalafil | 12 | $46,262 |
| Tadalafil | 33 | $41,805 |
| XareltoRivaroxaban | 15 | $22,215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $61 | $1,409,986159 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $318 | $1,248,26368 claims |
| BayerAdempas | $224 | $716,74354 claims |
| MerckWinrevair | $3,127 | $398,43028 claims |
| NovartisEntresto | $19 | $172,265154 claims |
| Boehringer IngelheimJardiance | $15 | $46,90152 claims |
| United Therapeutics CorporationAdcirca | $81 | $46,26212 claims |
| Johnson & JohnsonXarelto | $64 | $22,21515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
Other advanced heart failure and transplant cardiology in Pittsburgh
- Andrew PogozelskiPittsburgh$401K
- Srinivas MuraliPittsburgh$39K
- Sideris FacarosPittsburgh$21K
- Matthew LanderPittsburgh$16K
- Gavin HickeyPittsburgh$5K
- Jenna SkowronskiPittsburgh$4K
- Ravi RamaniPittsburgh$4K
- Miguel Pinilla VeraPittsburgh$4K
- Anjali VaidyaPhiladelphia$762K
- Brendan CarryDanville$424K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.